/

Empresas

Vo

No verificado

Volastra Therapeutics

Sobre qué escribimos

BiotecnologíaIndustriaMedicina - VariosOncologíaSalud

3 Comunicados de prensa

Ver todos los comunicados de prensa

07/01/2026

Mercado laboral

Industria

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

Medicina - Varios

Sanidad

Volastra Therapeutics Expands Clinical Development Program Following Encouraging KIF18A Inhibitor Data and Appoints New Chief Medical Officer to Lead Clinical Strategy

Fuente

Volastra Therapeutics

Editor

1.00

0

27/05/2025

Oncología

Salud

Medicina - Varios

Sanidad

Farmacéutica

Biotecnología

Mercado laboral

Industria

Volastra Therapeutics Announces Appointment of David P. Southwell as Chief Executive Officer

Fuente

Volastra Therapeutics

Editor

1.00

0

22/05/2025

Eventos

Oncología

Salud

Biotecnología

Medicina - Varios

Ciencia

Volastra Announces Initial Data from First-in-Human Phase I/II Trial of Novel KIF18A Inhibitor VLS-1488 to be Presented at 2025 ASCO Annual Meeting

Fuente

Volastra Therapeutics

Editor

1.00

0

Seguidores

0

Compatibilidad

0